Search is Powered by Google
Pharma Industry / Biotech Industry News

Supreme Court To Consider Whether To Bar Liability Lawsuits Against Pharmaceutical Companies

Main Category: Pharma Industry / Biotech Industry
Also Included In: Medical Malpractice / Litigation;  Regulatory Affairs / Drug Approvals
Article Date: 09 Sep 2008 - 8:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Health Professional:4 stars

4 (1 votes)

Article Opinions: 0 posts

The U.S. Supreme Court in November will consider whether to shield the makers of prescription and over-the-counter drugs from liability lawsuits, the Los Angeles Times reports. According to the Times, "the right to a civil jury trial has been a historic protection for consumers," but a recent series of lawsuits "has limited lawsuits against businesses," including a Supreme Court ruling in February that shields the manufacturers of government-approved medical devices from liability claims. In the past, "FDA had maintained that regulatory laws passed by Congress did not bar such lawsuits," but the agency "changed course" under the Bush administration and said that its oversight of drugs and medical devices barred most lawsuits regarding those products, the Times reports.

According to the Times, the Bush administration and the pharmaceutical industry now "stand on the verge of shutting down tens of thousands of lawsuits that have cost the industry billions of dollars in jury verdicts and settlements." After the Bush administration failed to persuade states or Congress to limit liability suits, it had federal agencies "reinterpret" laws to conclude that jury verdicts "would conflict with federal policy," and "[n]owhere is this approach having more effect than in the area of drugs and medical devices," the Times reports. Georgetown University law professor David Vladeck, formerly of Public Citizen, said, "This is a radical restructuring of the American civil justice system."

The case before the Supreme Court in November involves Diana Levine, who was awarded $6.7 million in damages from Wyeth after an anti-nausea drug was improperly injected into an artery and caused gangrene, which resulted in the amputation of her lower right arm and hand. Although the warning label urges extreme caution when administering Phenergan via injection, Levine sued the drugmaker, claiming that the company should have warned against injecting the drug under any circumstance.

The U.S. solicitor general, representing FDA on Wyeth's side, along with a broad coalition of business groups, including the U.S. Chamber of Commerce and the pharmaceutical industry, say that FDA had approved the label for Phenergan and that the Vermont jury did not have the authority or the expertise to decide whether a stronger warning was needed. Meanwhile, consumer rights advocates say lawsuits can alert the public to dangers that FDA might have missed, as well as provide compensation for injured patients (Savage, Los Angeles Times, 9/8).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.

© 2008 Advisory Board Company and Kaiser Family Foundation. All rights reserved.




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
U.S. FDA Approves Requip® XL™, The First And Only Oral Once-daily Non-ergot Dopamine Agonist For Parkinson's Disease
15 Jun 2008
GlaxoSmithKline announced the approval of Requip® XL™(ropinirole extended-release tablets) in the U.S. for the treatment of the signs and symptoms of idiopathic Parkinson's disease...


When Your Cycle Becomes a Major Headache
When Your Cycle Becomes a Major Headache

Cathy's gets as many as 12 to 15 headaches a month and they are all associated with her menstrual cycle. Migraines like hers tend to last longer and be more severe than other migraines. Figuring out what was triggering her headaches helped Cathy and her doctor come up with a successful treatment plan.

more videos are available in our health videos section.